Investigating the role of Follistatin in oral cancer progression
Official title: Single-cell profiling of Follistatin within the Tumor Landscape of Oral Squamous Cell Carcinoma
Funded at State University of New York at Buffalo · NIH-11067208 · Data updated 2026-11-12
This study is looking at how a protein called Follistatin affects mouth cancer, aiming to find new ways to diagnose and treat this type of cancer by understanding how it helps the cancer grow and spread.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | State University of New York at Buffalo NIH-funded |
| Lab location | 1 site (Amherst, United States) |
| Project start | January 1, 2025 |
| Project end | December 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $34,633 |
| NIH project number | 1F31DE034600-01 |
| Project ID | NIH-11067208 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with oral squamous cell carcinoma or those at high risk for developing this type of cancer.
✕Less likely to help
Patients with other types of cancers or those without a diagnosis of oral squamous cell carcinoma may not benefit from this research.
What this research studies
This research focuses on understanding how Follistatin (FST), a protein found in the body, influences the behavior of oral squamous cell carcinoma (OSCC), a type of cancer affecting the mouth. By analyzing cancer cells and their interactions with surrounding cells, the study aims to uncover how FST contributes to cancer growth and spread. Researchers will use advanced techniques, including gene manipulation and single-cell RNA sequencing, to explore the mechanisms by which FST may promote tumor aggression. The ultimate goal is to identify new biomarkers for early diagnosis and potential therapeutic targets for OSCC.
Why it matters
Potential benefit: If successful, this research could lead to improved diagnostic tools and targeted therapies for patients with oral squamous cell carcinoma.
How similar studies have gone: Previous research has shown promising results in understanding the role of similar proteins in cancer progression, suggesting that this approach may yield valuable insights.
Where this research is happening
-
State University of New York at Buffalo
Amherst, United States Active
Researchers
- Principal investigator: Sosa, Jennifer — State University of New York at Buffalo
- Study coordinator: Sosa, Jennifer
Related research
Other NIH-funded projects on the same topics.
-
Oral cancer recurrence predictor using tumor microbes and gene activity
This NIH grant explores how bacteria and immune signals inside oral cancer tumors relate to whether the cancer comes back, with the aim of making a practical risk predictor for patients.
-
Reducing bacteria inside oral cancer tumors to boost immune response
In people with head and neck cancer, this study tests whether lowering bacteria in tumors can help the immune system fight the cancer better.
-
REASON Score: an epigenetic and clinicopathologic approach to predict survival risk in early oral cancer
A new biomarker-based score using DNA methylation and clinicopathology to predict survival risk for people with early-stage oral squamous cell carcinoma.
-
New vulnerability in oral cancer linked to p53 loss
A cancer research grant is exploring a surprising weakness in head and neck cancer to help people with HPV-negative oral squamous cell carcinoma.
-
Mouth bacteria that may speed up oral cancer
This work looks at whether specific mouth bacteria help oral squamous cell carcinoma grow and spread in people who have or are at risk for oral cancer.
-
Targeting a stress-specific function of a DNA replication protein to boost oral cancer therapy
A short, targeted NIH grant explores a new way to make existing treatments work better for oral cancer by attacking a special function of a DNA replication protein that cancer cells rely on.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.